Inmune Bio, Inc. Files 8-K for Material Agreement

TL;DR

IBIO signed a material definitive agreement, more details to come.

AI Summary

On September 12, 2024, Inmune Bio, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits. The specific details of the agreement and financial information were not provided in this excerpt.

Why It Matters

This filing indicates a significant new agreement for Inmune Bio, Inc., which could impact its business operations and financial future.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the lack of specific details in this excerpt necessitates a medium risk assessment.

Key Players & Entities

• Inmune Bio, Inc. (company) — Registrant
• September 12, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per shares INMB The NASDAQ Stock Ma
• $5.50 — Shares were sold at a purchase price of $5.50 per share and related Warrant for Inves
• $6.50 — e and related Warrant for Investors and $6.50 per share and related Warrant for Insid
• $13,000,000, b — roceeds to the Company of approximately $13,000,000, before deducting placement agent fees and
• $6.40 — ant. The exercise price the Warrants is $6.40 per share subject to adjustment as prov
• $5.0 million — ondition Measurement Period is at least $5.0 million per day. Pursuant to a placement agenc
• $50,000 — ng in an aggregate amount not to exceed $50,000. We have also agreed to reimburse the P
• $25,000 — ble expenses in an amount not to exceed $25,000. The Offering is expected to close on

Filing Documents

• ea0214504-8k_inmune.htm (8-K) — 36KB
• ea021450401ex4-1_inmune.htm (EX-4.1) — 114KB
• ea021450401ex5-1_inmune.htm (EX-5.1) — 14KB
• ea021450401ex10-1_inmune.htm (EX-10.1) — 177KB
• ea021450401ex10-2_inmune.htm (EX-10.2) — 47KB
• ea021450401ex99-1_inmune.htm (EX-99.1) — 10KB
• ex5-1_001.jpg (GRAPHIC) — 15KB
• ex99-1_001.jpg (GRAPHIC) — 4KB
• 0001213900-24-078783.txt ( ) — 695KB
• inmb-20240912.xsd (EX-101.SCH) — 3KB
• inmb-20240912_lab.xml (EX-101.LAB) — 33KB
• inmb-20240912_pre.xml (EX-101.PRE) — 22KB
• ea0214504-8k_inmune_htm.xml (XML) — 4KB

01 Entry into a Material Definitive

Item 1.01 Entry into a Material Definitive Agreement. On September 12, 2024, INmune Bio, Inc. (the "Company"), entered into securities purchase agreements (the "Purchase Agreements") with certain investors (the "Investors"), and directors officers and employees of the Company (the "Insiders" together with the Investors, the "Purchasers) for the purchase and sale of an aggregate of 2,341,260 shares of the Company's common stock (the "Shares") and common stock warrants (the "Warrants") to purchase 2,341,260 shares of its common stock (the "Warrant Shares" and collectively with the Shares and the Warrants, the "Securities") in a registered direct offering (the "Offering"). The Shares were sold at a purchase price of $5.50 per share and related Warrant for Investors and $6.50 per share and related Warrant for Insiders, for aggregate gross proceeds to the Company of approximately $13,000,000, before deducting placement agent fees and expenses. The Warrants are exercisable on or after March 16, 2025 (the "Initial Exercise Date") and will terminate on March 16, 2030 unless such termination is accelerated pursuant to the terms of the Warrants (the "Termination Date"), provided, however, in the event that the Warrant is held by Insiders and the Termination Date is during a period that such Insiders are subject to a blackout with respect to trading in the Company's common stock, such Insiders will have an additional 60 days from the termination of the blackout to exercise the Warrant. The exercise price the Warrants is $6.40 per share subject to adjustment as provided in the Warrant (the "Exercise Price"). After the Initial Exercise Date, provided that the Equity Conditions (as defined in the Purchase Agreement) have been satisfied, the Termination Date shall be subject to acceleration upon the occurrence of both (i) the Company's public announcement of reporting of positive top line data (EMACC p-value of less than or equal to 0.05) in the Phase 2 Alzheimer's program of

01 Other

Item 8.01 Other Events. On September 13, 2024, the Company issued a press release regarding the Offering. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

01 Financial

Item 9.01 Financial Exhibit No Exhibit 4.1 Form of Warrant 5.1 Opinion of Sichenzia Ross Ference Carmel LLP 10.1 Form of Securities Purchase Agreement 10.2 Form of Placement Agency Agreement 99.1 Press release, dated September 13, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMUNE BIO INC. Date: September 16, 2024 By: /s/ David Moss David Moss Chief Financial Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR